| P2093 | author name string | Xianquan Zhang | |
| | Mingfeng He | |
| | Weidong Fan | |
| P2860 | cites work | Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. | Q51522634 |
| | Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01) | Q53455838 |
| | Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results | Q83393818 |
| | Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients | Q83556022 |
| | Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results | Q87419544 |
| | Cancer statistics, 2012 | Q27860574 |
| | Quantifying heterogeneity in a meta-analysis | Q27860672 |
| | Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial | Q30416847 |
| | American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer | Q33827254 |
| | Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis | Q34330558 |
| | Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. | Q34414177 |
| | Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis | Q34583705 |
| | Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer | Q34962888 |
| | Bisphosphonates: preclinical review | Q35905959 |
| | The clinical course of bone metastases from breast cancer | Q36027636 |
| | Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer | Q36075231 |
| | Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates | Q36498963 |
| | New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects | Q36648924 |
| | Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark | Q36740469 |
| | Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice | Q36897441 |
| | Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer | Q37121724 |
| | Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. | Q37146402 |
| | The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials | Q37958566 |
| | Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases | Q39415860 |
| | Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model | Q40538169 |
| | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. | Q42603658 |
| | Breast-cancer adjuvant therapy with zoledronic acid | Q42620139 |
| | Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. | Q44575984 |
| | Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial | Q45496960 |
| | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy | Q46417627 |
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| | zoledronic acid | Q218507 |
| | bisphosphonate | Q412205 |
| | imidazole | Q1659847 |
| | breast neoplasm | Q23929670 |
| | meta-analysis | Q815382 |
| | systematic review | Q1504425 |
| | bone density conservation agents | Q50430327 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 80 | |
| P577 | publication date | 2013-10-23 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis | |
| P478 | volume | 6 | |